{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:01:06Z","timestamp":1783720866223,"version":"3.55.0"},"reference-count":32,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Avelumab maintenance therapy was approved in Japan for curatively unresectable urothelial carcinoma (UC) without progression after prior platinum\u2010based chemotherapy (PBC) based on results from the JAVELIN Bladder 100 phase 3 trial. We report post hoc analyses of post\u2010marketing surveillance (PMS) data in subgroups defined by age, prior PBC regimen, and best overall response (BOR) to prior PBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with curatively unresectable UC who received \u2265\u20091 dose of avelumab maintenance in Japan between February and December 2021 were evaluated. The primary objective was to evaluate safety based on prespecified adverse drug reactions (ADRs). The secondary objective was to evaluate effectiveness, including time to treatment failure (TTF; discontinuation for any reason) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The analysis population included 453 patients. In patients aged \u2264\u200964 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200975), 65 to 74 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009198), or \u2265\u200975 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009180) years, prespecified ADRs occurred in 17 (22.7%), 69 (34.9%), and 58 (32.2%); median TTF was 4.8, 4.4, and 4.9\u2009months; and 12\u2010month OS rates were 77.6%, 82.7%, and 72.6%, respectively. In patients with prior cisplatin + gemcitabine (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009267), carboplatin + gemcitabine (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009163), or dose\u2010dense methotrexate, vinblastine, doxorubicin, and cisplatin (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099) treatment, prespecified ADRs occurred in 93 (34.8%), 45 (27.6%), and 3 (33.3%); median TTF was 4.6, 4.6, and 5.1\u2009months; and 12\u2010month OS rates were 79.6%, 73.8%, and 88.9%, respectively. In patients with prior complete response (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200947), partial response (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009242), or stable disease (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009149), prespecified ADRs occurred in 16 (34.0%), 79 (32.6%), and 45 (30.2%); median TTF was 5.2, 4.6, and 4.6\u2009months; and 12\u2010month OS rates were 89.4%, 76.3%, and 75.8%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In this PMS population, safety and effectiveness were observed with avelumab maintenance therapy across subgroups defined by age, prior PBC regimen, or BOR to prior PBC. Findings support the favorable benefit\u2013risk profile of avelumab maintenance in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>University Hospital Medical Information Network Clinical Trials Registry (UMIN\u2010CTR: UMIN 43435)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71177","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:48:27Z","timestamp":1761817707000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Subgroup Analyses of Post\u2010Marketing Surveillance Data by Age, Prior Chemotherapy Regimen, and Best Overall Response to Prior Chemotherapy"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-191X","authenticated-orcid":false,"given":"Masayoshi","family":"Nagata","sequence":"first","affiliation":[{"name":"Department of Urology Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Urology St. Marianna University School of Medicine  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taito","family":"Ito","sequence":"additional","affiliation":[{"name":"Medical Department, Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sato","sequence":"additional","affiliation":[{"name":"Research &amp; Development, Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie","family":"Ogi","sequence":"additional","affiliation":[{"name":"Global Development Operations, Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Morita","sequence":"additional","affiliation":[{"name":"Global Patient Safety Japan, Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kajita","sequence":"additional","affiliation":[{"name":"Medical Department, Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine University of Tsukuba  Ibaraki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_11_3_1","unstructured":"National Cancer Center Japan \u201cProjected Cancer Statistics \u201d (2024) https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/short_pred_en.html."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15473"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71264"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02067-8"},{"key":"e_1_2_11_8_1","volume-title":"SEER Cancer Stat Facts: Bladder Cancer","author":"National Cancer Institute","year":"2025"},{"key":"e_1_2_11_9_1","unstructured":"National Comprehensive Cancer Network \u201cNCCN Clinical Practice Guidelines in Oncology: Bladder Cancer v1.2025 \u201dhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.026"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15362"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01792"},{"key":"e_1_2_11_15_1","unstructured":"Japanese Urological Association \u201cSupplement to Clinical Practice Guidelines for Bladder Cancer [2019 Update] \u201d (2021) https:\/\/www.urol.or.jp\/lib\/files\/other\/guideline\/39_bladder_cancer_2019_rev2021_info.pdf."},{"key":"e_1_2_11_16_1","volume-title":"Prescribing Information","author":"Bavencio (avelumab)","year":"2022"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.09.014"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100068"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0540-8"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0298"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-1065"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4570"},{"key":"e_1_2_11_23_1","first-page":"939","article-title":"Bladder Cancer in the Elderly Patient: Challenges and Solutions","volume":"10","author":"Guancial E. A.","year":"2015","journal-title":"Clinical Interventions in Aging"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02099-0"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4559"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.508"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1020"},{"key":"e_1_2_11_28_1","unstructured":"Ministry of Health Labor and Welfare of Japan \u201cMinisterial Ordinance on Standards for Conducting Post\u2010Marketing Surveillance and Testing of Pharmaceuticals \u201d (2022) https:\/\/elaws.e\u2010gov.go.jp\/document?lawid=416M60000100171_20220520_504M60000100084."},{"key":"e_1_2_11_29_1","unstructured":"Merck Biopharma Co. Ltd. Tokyo Japan an affiliate of Merck KGaA Darmstadt Germany \u201cBavencio Intravenous Infusion 200 mg Drug Risk Management Plan \u201d (2020) https:\/\/www.pmda.go.jp\/RMP\/www\/380079\/19ec56b7\u20108ab2\u201048fa\u2010b2c6\u20108907bf67f19e\/380079_4291438A1022_012RMP.pdf."},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr156"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.05.028"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.08.009"},{"key":"e_1_2_11_33_1","unstructured":"Astellas Pharma \u201cJapan's MHLW Approves PADCEV (Enfortumab Vedotin) for Advanced Urothelial Cancer \u201d (2021) https:\/\/www.astellas.com\/en\/news\/17206."}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71177","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:29:02Z","timestamp":1777530542000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":32,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/cam4.71177"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71177","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"2025-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71177"}}